Home > Boards > US Listed > Medical - Healthcare > Precision Therapeutics Inc. (AIPT)

Uptick Newswire Hosts Precision Therapeutics Inc. on The

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Paullee Member Profile
 
Followed By 13
Posts 1,759
Boards Moderated 0
Alias Born 11/25/03
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/13/2019 8:46:12 AM
Predictive Oncology Inc. (Formerly Precision Therapeutics) Names Amelia Warner, Pharm.D., RPh, as Interim Chief Operating Off... GlobeNewswire Inc. - 6/12/2019 8:00:00 AM
Precision Therapeutics Announces Corporate Name Change To Predictive Oncology Inc. GlobeNewswire Inc. - 6/11/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 4:12:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2019 4:01:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/28/2019 5:45:51 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 5/24/2019 4:10:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/24/2019 3:47:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/23/2019 5:15:04 PM
Precision Therapeutics’ Helomics Division Selected by AccuGenomics as Preferred Lab Partner for NIIMBL Grant GlobeNewswire Inc. - 5/21/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2019 4:03:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2019 9:02:17 AM
Precision Therapeutics Gains Extension for Nasdaq Compliance GlobeNewswire Inc. - 5/17/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/15/2019 4:35:58 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2019 4:07:54 PM
Precision Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/15/2019 4:05:00 PM
Precision Therapeutics to Report First Quarter 2019 Financial Results and Provide Company Update on Wednesday, May 15, 2019 GlobeNewswire Inc. - 5/13/2019 1:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 5:17:36 PM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 4/24/2019 4:56:15 PM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 4/24/2019 4:31:32 PM
Precision Therapeutics’ Subsidiary Helomics and National Alopecia Areata Foundation Sign Services Agreement to Provide Next... GlobeNewswire Inc. - 4/18/2019 8:45:00 AM
Precision Therapeutics’ Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Receive Alberta Innovates Product Dem... GlobeNewswire Inc. - 4/16/2019 8:45:00 AM
Precision Therapeutics’ Subsidiary, Helomics® Corporation, and SpeciCare, Inc. to Study Innovative Personalized Medicine... GlobeNewswire Inc. - 4/11/2019 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/10/2019 5:16:33 PM
Precision Therapeutics’ Subsidiary Helomics to Collaborate with Viome to Explore the Impact of the Gut Microbiome on Ovaria... GlobeNewswire Inc. - 4/9/2019 8:45:00 AM
Paullee   Thursday, 04/11/19 11:13:27 AM
Re: None
Post # of 4057 
Uptick Newswire Hosts Precision Therapeutics Inc. on The Stock Day Podcast to Discuss Massive Revenue Increases

ACCESSWIRE•April 11, 2019
AIPT) ("the Company"), a company with business lines that include applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic, and biotech industries; and the production and sales of the FDA-approved automated STREAMWAY® System, a direct-to-drain medical fluid disposal system. CEO and Director, Dr. Carl Schwartz, joined Stock Day host Everett Jolly.">PHOENIX, AZ / ACCESSWIRE / April 11, 2019 / Uptick Newswire Stock Day Podcast welcomed Precision Therapeutics Inc. (NASDAQ: AIPT) ("the Company"), a company with business lines that include applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic, and biotech industries; and the production and sales of the FDA-approved automated STREAMWAY® System, a direct-to-drain medical fluid disposal system. CEO and Director, Dr. Carl Schwartz, joined Stock Day host Everett Jolly.

To begin the interview, Jolly asked Dr. Schwartz to provide some background information about the Company. Dr. Schwartz explained that the Company has four rapidly growing divisions, including Skyline Medical, Tumor Genesis, and Helomics Corporation. "We are excited about each of these divisions and their rapid growth as we continue to execute on our business strategy," stated Dr. Schwartz.

Dr. Schwartz then shared exciting new developments for their Skyline Medical division and explained that the Company has recently expanded the staff of their domestic sales force. Dr. Schwartz also added that the Company has established its international headquarters in Belgium and now has distributors and sales representatives in over 20 countries. Recently, Skyline Medical even received word that India has made the use of their technology mandatory in all hospitals.

"We have been receiving orders for our machines from around the world," added Dr. Schwartz. He continued to explain that the Company has made significant improvements to their sales and marketing approach, which is reflected by their increased revenues.

Dr. Schwartz then updated listeners on the Company's division, Tumor Genesis. He stated, "Tumor Genesis was formed to create a new approach to grow tumors outside of the body, in which the tumor is fooled into thinking it is still in the body and acts and responds much more naturally to stimuli, such as drugs". He continued to explain that this approach is intended to be used in the development of treatments for ovarian tumors and that the Company is moving forward rapidly with this approach.

Dr. Schwartz continued by sharing more information about the Company's newest subsidiary, Helomics Corporation. He explained that this subsidiary is extremely valuable due to the drug response data it can provide regarding tumors, especially ovarian tumors. Helomics also provides this information to referring oncologists in an effort to create a more individualized treatment program for each patient. With the wealth of information provided by Helomics, the Company plans to use this data to assist in the development of new therapies.

"AIPT is determined to bring real hope to thousands of women with these tumors. The entire focus of both Helomics and Tumor Genesis is ovarian cancer," added Dr. Schwartz.

Dr. Schwartz then expanded on the experienced team behind the Company, which is full of industry leading experts.

Jolly then noted that the Company has experienced massive revenue growth between 2017 and 2018 and asked what lead to this substantial increase. Jolly also asked Dr. Schwartz about recent international agreements. Dr. Schwartz explained that the increased revenues reflect the Company's increasing machine sales, as well as new practices with their disposables. He then shared that the Company has expanded into Australia, which has shown great excitement for the use of the Company's technology and its potential.

"All of our divisions are solid. Their approach is accurate. We should begin to see really solid results in the very near future," closed Dr. Schwartz.

https://upticknewswire.com/featured-interview-ceo-dr-carl-schwartz-of-precision-therapeutics-inc-nasdaq-aipt-3/">To hear Dr. Carl Schwartz's entire interview, follow the link to the podcast here: https://upticknewswire.com/featured-interview-ceo-dr-carl-schwartz-of-precision-therapeutics-inc-nasdaq-aipt-3/



About Precision Therapeutics Inc.

AIPT) operates in two business lines, operated through four wholly-owned subsidiaries. The company's two business lines include applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic, and biotech industries; and the production and sales of the FDA-approved automated STREAMWAY® System, a direct-to-drain medical fluid disposal system. For additional information, please visit www.precisiontherapeutics.com.">Precision Therapeutics (AIPT) operates in two business lines, operated through four wholly-owned subsidiaries. The company's two business lines include applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic, and biotech industries; and the production and sales of the FDA-approved automated STREAMWAY® System, a direct-to-drain medical fluid disposal system. For additional information, please visit www.precisiontherapeutics.com.

Precision's recently acquired, wholly owned subsidiary, Helomics, is a personalized healthcare company dedicated to improving the standard of care for cancer patients (especially gynecological) through innovative research and development partnerships with pharmaceutical, diagnostic, biotechnology, and academic organizations, leading to better and more personalized treatments and diagnostic technologies cancer. Helomics' CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and a proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to our client's specific needs.

Its second wholly-owned subsidiary, TumorGenesis, has developed a new rapid approach to growing tumors in the laboratory, which essentially "fools" the cancer cells into thinking they are still growing inside the patient.

www.skylinemedical.com.">Finally, the Company's STREAMWAY System fully automates the collection, measurement, and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S. virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. For additional information, please visit www.skylinemedical.com.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist